Stem cell therapy for critical limb ischaemia - a review

Area of Science:

• Regenerative Medicine
• Vascular Biology

Background:

• Critical limb ischemia (CLI) is a severe condition leading to high amputation rates and poor quality of life.
• Standard treatments for CLI are often ineffective, necessitating novel therapeutic approaches.

Purpose of the Study:

• To explore the potential of stem cell therapy as a novel treatment for critical limb ischemia.
• To review the current evidence for stem cell therapy in improving limb vascularity.

Main Methods:

• Review of preclinical animal studies and clinical trials investigating stem cell therapy for CLI.
• Analysis of growth factors like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF-1) in promoting neoangiogenesis.

Main Results:

• Stem cell therapy, particularly with mesenchymal stem cells (MSCs), has demonstrated efficacy in animal models for enhancing limb vascularity.
• Clinical studies suggest potential benefits of stem cell therapy for patients with CLI.

Conclusions:

• Stem cells, especially MSCs with their immunomodulatory properties, represent a promising therapeutic avenue for CLI.
• Key challenges including optimal dosage, delivery methods, and safety profiles require further investigation before widespread clinical adoption.